Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

copper Cu 64-PSMA-I&T

A radioconjugate composed of PSMA-I&T, a human prostate-specific membrane antigen (PSMA)-targeting ligand linked to the bifunctional, macrocyclic chelating agent 1,4,7,10-tetraazacyclododecane-1-(glutamic acid)-4,7,10-triacetic acid (DOTAGA; DOTA-GA), labeled with the positron emission tomography (PET) tracer copper Cu 64, with potential use as a tracer for PSMA-expressing tumors during positron emission tomography (PET)/computed tomography (CT). Upon administration of copper Cu 64-PSMA-I&T, PSMA-I&T targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells can be detected during PET/CT imaging. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:64Cu-PSMA I&T
copper Cu 64 PSMA-I&T
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search